ArticleBreast cancer research and treatment2025
Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTrastuzumab therapy carries a risk of acute cardiotoxicity, particularly when combined with anthracyclines. To date, no study has assessed hypertension as a potential long-term adverse effect of trastuzumab therapy in adolescent and young adult (AYA) cancer survivors.
methodsWe identified all female AYAs aged 15-39 years diagnosed with first primary invasive breast cancer between 2006 and 2020 in Kaiser Permanente Northern and Southern California, who survived at least 2 years post-diagnosis. Patients were categorized into two groups: those who received chemotherapy plus trastuzumab and those who received chemotherapy alone. We examined hypertension occurrence starting 2 years post-diagnosis, compared the 2-5-year cumulative incidence of hypertension between the trastuzumab and non-trastuzumab groups, and evaluated associated risk factors.
resultsAmong 2382 female AYAs with breast cancer, 33.0% received trastuzumab. The 2-5-year cumulative incidence of hypertension did not differ between the trastuzumab (6.79%, 95% Confidence Interval [CI] 4.96-8.99%) and non-trastuzumab (7.85%, CI 6.41-9.48%) groups, p = 0.67. Trastuzumab was not associated with hypertension (hazard ratio (HR) = 1.01, CI 0.731-1.38) in multivariable analysis. Factors associated with higher hypertension included older age at diagnosis (35-39 vs. 15-34y), non-Hispanic Black or non-Hispanic Asian race/ethnicity (vs. non-Hispanic White), overweight or obesity (vs. underweight or normal weight), smoking, and endocrine therapy. History of diabetes and dyslipidemia showed borderline association with hypertension.
conclusionTrastuzumab was not associated with new-onset hypertension among AYA breast cancer survivors. However, sociodemographic and clinical factors significantly contributed to hypertension risk, highlighting the importance of interventions targeting modifiable risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.